Cargando…

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study

We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccardi, A, Mora, O, Tinelli, C, Valentini, D, Brugnatelli, S, Spanedda, R, De Paoli, A, Barbarano, L, Di Stasi, M, Giordano, M, Delfini, C, Nicoletti, G, Bergonzi, C, Rinaldi, E, Piccinini, L, Ascari, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374495/
https://www.ncbi.nlm.nih.gov/pubmed/10755397
http://dx.doi.org/10.1054/bjoc.1999.1087
_version_ 1782154467155640320
author Riccardi, A
Mora, O
Tinelli, C
Valentini, D
Brugnatelli, S
Spanedda, R
De Paoli, A
Barbarano, L
Di Stasi, M
Giordano, M
Delfini, C
Nicoletti, G
Bergonzi, C
Rinaldi, E
Piccinini, L
Ascari, E
author_facet Riccardi, A
Mora, O
Tinelli, C
Valentini, D
Brugnatelli, S
Spanedda, R
De Paoli, A
Barbarano, L
Di Stasi, M
Giordano, M
Delfini, C
Nicoletti, G
Bergonzi, C
Rinaldi, E
Piccinini, L
Ascari, E
author_sort Riccardi, A
collection PubMed
description We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57–2.42;P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months;P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. © 2000 Cancer Research Campaign
format Text
id pubmed-2374495
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23744952009-09-10 Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study Riccardi, A Mora, O Tinelli, C Valentini, D Brugnatelli, S Spanedda, R De Paoli, A Barbarano, L Di Stasi, M Giordano, M Delfini, C Nicoletti, G Bergonzi, C Rinaldi, E Piccinini, L Ascari, E Br J Cancer Regular Article We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57–2.42;P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months;P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. © 2000 Cancer Research Campaign Nature Publishing Group 2000-04 2000-03-06 /pmc/articles/PMC2374495/ /pubmed/10755397 http://dx.doi.org/10.1054/bjoc.1999.1087 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Riccardi, A
Mora, O
Tinelli, C
Valentini, D
Brugnatelli, S
Spanedda, R
De Paoli, A
Barbarano, L
Di Stasi, M
Giordano, M
Delfini, C
Nicoletti, G
Bergonzi, C
Rinaldi, E
Piccinini, L
Ascari, E
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
title Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
title_full Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
title_fullStr Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
title_full_unstemmed Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
title_short Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
title_sort long-term survival of stage i multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374495/
https://www.ncbi.nlm.nih.gov/pubmed/10755397
http://dx.doi.org/10.1054/bjoc.1999.1087
work_keys_str_mv AT riccardia longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT morao longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT tinellic longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT valentinid longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT brugnatellis longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT spaneddar longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT depaolia longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT barbaranol longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT distasim longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT giordanom longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT delfinic longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT nicolettig longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT bergonzic longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT rinaldie longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT piccininil longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT ascarie longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy
AT longtermsurvivalofstageimultiplemyelomagivenchemotherapyjustafterdiagnosisoratprogressionofthediseaseamulticentrerandomizedstudy